HIGH SCHOOL EDITION
Journal of Student Research

Volume 13 Issue 3 (2024)

Implementation of AI and ML for Oncology with an Analysis of Biotechnology, Nanotechnology & POC

Srinija Chukkapalli

Leander High School

ABSTRACT

In recent years, the integration of artificial intelligence (AI) and machine learning (ML) has significantly advanced cancer research and treatment. By utilizing deep learning (DL) and natural language processing (NLP), researchers are uncovering new patterns in large datasets, leading to more accurate diagnoses and personalized treatment plans. The synergy of nanotechnology further augments these advancements by improving drug delivery systems and enabling non-invasive tumor characterization. Additionally, point-of-care care diagnostics and global healthcare solutions are examined as vital points for improving cancer care, especially in underprivileged regions. The paper also addresses the ethical limitations that have arisen from applying artificial intelligence and machine learning to oncology, highlighting the need for careful implementation and regulation to maximize benefits while minimizing risks. This paper explores the transformative role of AI and ML in enhancing clinical outcomes, particularly through genomics, proteomics, and bioinformatics.

Introduction

Cancer remains one of the most formidable challenges in modern medicine, responsible for millions of deaths worldwide each year. Over the decades, cancer research has evolved from basic anatomical observations to sophisticated molecular and genetic studies (Nelakurthi et. al, 2023). Recently, the advent of artificial intelligence (AI) and machine learning (ML) has revolutionized this field, marking a significant shift towards precision medicine. These technologies offer unprecedented capabilities in data analysis, enabling researchers to process vast amounts of information from genomics, proteomics, and electronic medical records (Yim et. al, 2016). AI and ML have significantly improved the accuracy of cancer diagnoses, personalized treatment plans, and patient outcome predictions. The integration of AI with nanotechnology has further enhanced drug delivery systems and facilitated non-invasive tumor characterization. Despite these advancements, cancer remains a leading cause of morbidity and mortality, highlighting the need for continued research and innovation. Historically, scientists have witnessed a trend where the 1990s and early 2000's witnessed the rapid mobilization of AI algorithms, as opposed to the 2010s, when big data made AI more accessible as interventions towards various industries – like oncology, biomedical sciences, precision medicine, and more.

Implementation of AI and ML to Improve Clinical Outcomes of Detecting Cancer

Researchers have exemplified the efficacy of AI in applying deep-level information towards genomics, which has successfully enabled clinicians to understand the different forms of tumor screening, onset, treatment, and predictions to help leverage clinical outcomes (Liao et al., 2023). Two revolutionary technologies that have the potential to completely change the treatment of cancer and oncological research are artificial intelligence (AI), which includes machine learning (ML), and natural language processing (NLP). (Liao et al., 2023) AI has great potential to uncover patterns and important information by utilizing large data from different fields, including radiomics, transcriptomics, proteomics, genomes, and digital pathology. Utilizing deep learning (DL) and advanced machine learning (ML) techniques in addition to integrating multi-omics data, AI-driven methods offer customized solutions for every patient, enabling personalized medicine (PM) treatments and comprehensive tumor analysis for diagnosis, classification, prognosis prediction, and treatment selection. Similar to this, natural language processing (NLP) is a ground-breaking invention that has the potential to reveal significant knowledge that is concealed deep within unstructured clinical data from electronic medical records (EMRs) by converting free-text narratives into structured data, which is essential for oncology research and clinical decision-making. (Yim et al., 2016). These technologies can be improved and incorporated into clinical workflows by oncologists, ML specialists, and NLP scientists working together. This will accelerate procedures like case identification, staging, and outcome evaluation. The combination of AI, ML, and NLP has the potential to revolutionize the way that cancer is treated globally by enabling greater personalized and specialized treatment.

Analysis of Certain Biomarkers to Analyze Early Onset

The field of cancer detection and therapy has changed dramatically as a result of the merging of proteomics and bioinformatics, which has also had a substantial impact on biological research (Nelakurthi et al., 2023). Proteomics has brought along innovative techniques like proteome pattern analysis, which has great potential for early disease identification, especially in difficult-to-treat cancers like ovarian cancer. Rather than focusing on the specific biomarkers, this new method focuses on the complex protein patterns, allowing for high-throughput, quick analysis of clinical data. Proteomics has great potential, but there are still issues that need to be resolved. For example, the detection of biomarkers with low abundance requires increased sensitivity, and assessing biofluid matrices such as serum and plasma is difficult at times. (Nelakurthi et al., 2023) Meanwhile, bioinformatics has become a vital tool for utilizing the abundance of biological data to improve the early identification of cancer. Comprehensive molecular profiling of tumors is made possible by bioinformatics by deploying advanced computational techniques and integrating multiple omics data sets, such as genomics and proteomics. This enhances patient outcomes by enabling clinicians to customize specific prognoses and therapy (Conrads et al., 2023). Proteomics and bioinformatics work in unison to provide complementary approaches to deciphering the complexity of cancer biology, opening up new possibilities for precision medicine research and the identification of new biomarkers. (Conrads et al., 2023) Their joint efforts have great potential to improve cancer management overall, treatment effectiveness, and early detection, leading to the emergence of precision oncology. Despite the radical findings behind the optimal detection of biomarkers which subsequently leads to improved efficiency in detecting cancer, such findings have limitations in diversifying their subset of results towards the variations amongst cancer such as ovarian cancer, and individual patients, with further study required to improve diagnostic and treatment strategies for all patients.

Composition of Biotechnology and AI for Cancer Research (Nanotechnology)

Through the introduction of Artificial Intelligence and Nanotechnology, the studies behind “Precision Medicine” have undergone a significant evolution in the studies to better treat cancer patients, through implementing nanomaterials that can be leveraged on a grand scale (Adir, 2020). For instance, in recent advancements, diagnostic nanomaterials have been introduced to ensure that the treatment outcome is improved upon, through leading to optimal interactions with the target drug, improved fluidity in the biological fluids as well as improved functions of the immune system and cell membranes. Advancements in nanotechnology have led to an improved understanding of not only cancer biology but also inside the patient’s body by opening a branch of computer science within “human intelligence” where researchers are able to discover patterns and classify data to find new medical imaging, nanoinformatics and computational methods. (Adir, 2020) So how exactly is AI applied in optimizing the processes of creating tailored drug delivery and systems? Researchers have witnessed that through applying AI in the form of Artificial Neural Networks, the sequences of the accuracy level have risen to a 97%, depending on the DNA coverage level. For instance, in the form of amino-acid identification, support vector machines and algorithms are able to better classify signals of amino acids so that they can classify new signals of amino acid sequences in the future. (Adir, 2020)



Figure 1: Modules for Biomarker Detection. Adir, 2020

Technological Theranostics for Targeting and Tumor Characteristics (Morphology, Biopsy)

Recent research findings have been exemplifying novel interventions entailing targeting tumor through targeted drug delivery and nanotechnology-based drug delivery systems through relying upon different forms of nanomedicine in aiding with addressing biological barriers in drug delivery systems. (Arranja et al., 2017) With the recent advancement in technological modalities, such as computed tomography, ultrasound, PET scans as well as other forms of tomography, researchers must pay attention to the cost-effectiveness, time-effectiveness, as well as the adaptability of these forms of imaging systems. (Arranja et al., 2017) However, with the recent advancements in nanomedicine which has been complemented by technological innovation, research has fostered greater accessibility and efficacy in creating certain nanomedicines that can carry the physicochemical properties in manipulating and keeping the target tissue consistent, which will ensue radical success in not only clinical trials and R&D, but for treating patients with various aggressive tumors and genetic mutations. Other researchers have paid attention to significant advancements in biomedical imaging to ensure that diagnostics allow for non-invasive visualization of certain human internal organs and tissues through relying upon molecular imaging and biomedical imaging in establishing the best possible therapeutic outcomes. (Arranja et al., 2017) For instance, through the technological advancements in allowing imaging agents to be implemented into the pharmacodynamics of drug deliveries with appropriate functionality of MRI and other imaging tools like magnetic resonance imaging (MRI), healthcare is able to witness the non-invasive monitoring of gene delivery with MRI that they were not able to witness a decade ago.

Advancements in Point-of-Care Diagnostics for Cancer Research

In order to create rapid and reliable tools to serve cancer research, new point-of-care technology (POC) is being utilized to analyze and create an optimal treatment plan for cancer patients (Hayes et. al, 2018). Currently, most diagnostic testing carried out in hospital-based laboratories requires trained personnel and costly equipment to operate. By transitioning to POC devices, these tests become simplified, which reduces the overall cost of personnel, materials, and equipment. Through effective use of biomarkers in POC devices, the current cancer screening programs in hospitals globally can be improved. POC technology has strategically altered the diagnosis of gastrointestinal cancer. Methods such as fecal occult blood, fecal proteins, volatile organic compounds, pyruvate kinase isoenzyme type M2, tumor markers and DNA analysis. Fecal occult blood testing has a reported sensitivity of 66%-85% and specificity greater than 95%. (Hayes et al., 2018) Another group of researchers looked into other forms of POC systems – for instance, a physicochemical transducer, or magnetic transducer, that is capable of transmitting electronic signals. (Soper et al2006) From analyzing the POC systems, researchers were able to see how they led to better screening efficacy and accuracy for helping at-risk patients, in ensuring that disease recurrence was limited as much as possible, and solutions were made more accessible to cancer centers. For instance, from introducing POC systems that had a higher efficacy of "targeting" biomarkers in diagnostic assays, then researchers were able to analyze these biomarkers and investigate certain composition of antigens like parameters, peptides, and polymers to better create diagnostics for the population of molecules, in understanding how cancer cells are differentiated from regular normal cells. (Soper et al., 2006)

Global Healthcare Solutions for Underprivileged Nations for Oncology Development and Research

Despite the radical increase in over 10 million individuals being diagnosed with cancer, research statistics have shown that over half of them reside in developing countries. For instance, these statistics revealed that there were over 12.4 million new cases of cancer, with nearly 2/3 of the estimated deaths belonging in low and middle-income countries, where these households bear the most significant burden of new cancer cases. (Moten et al., 2014) Results have exemplified that lower and middle income countries lag behind more affluent nations due to the lack of awareness, prevention and early detection modules available, even when most forms of cancer are easily-treatable and preventable, with proper knowledge and awareness. (Moten et al., 2014) For instance, some of the most essential solutions lie in establishing the appropriate health infrastructures to ensure that there are more opportunities to educate, diagnose, and extend alternative therapeutics as well as surgery to patients in low-income nations. For instance, federal policies today have released the potential of nanotechnology to be introduced to have highly-sensitive pathogen detection platforms, as endorsed by the US National Institutes of Health and the National Cancer Institute Alliance for Nanotechnology in Cancer, in applying different forms of nanotechnology in appropriately-diagnosing and treating diseases. (Moten et al., 2014) As conventional forms of medicine are largely inaccessible to these developing nations, it is essential to distribute these nanomaterials and laboratory equipment, coupled by medical expertise, to improve and bolster the health outcomes in these limited communities.

Ethics, Discussion and Limitations

When diversifying these results related to the prominence of AI in cancer research, it is also crucial to consider ethical limitations as much of the data and dataset received that has been integrated into cancer research is considered to be private, and confidential. Thus, there may be the need to properly disclose patients of potential risks in data breaches, as well as the limitations surrounding limited informed consent. As seen in the results entailing the global health outcomes of lower income nations having less accessible cancer research, treatment and clinical outcomes, in many cases, the research studies cannot be diversified towards all health populations and communities. In addition to this, when applying novel biotechnological interventions, it is necessary for researchers to also consider regulations in ensuring that genetic modifications, or applying AI and ML metrics towards cancer treatment outcomes have their risks minimized as much as possible to prevent ethical issues from affecting the efficacy of studies and results obtained. Additionally, another limitation to consider is that when applying AI and predictive modeling for cancer, there may be some ethical issues entailing gender, race and ethnicity diversification as these modules may not be as effective on certain races or gender, which could lead to gender and ethical disparities in accessibility.

Conclusion

In conclusion, amidst the radical advancements in cancer research, researchers have been able to pave the way for clinical trials and advancements through applying AI and ML towards improving clinical outcomes. Specifically, researchers are now capable of analyzing biomarkers to construct a more accurate cancer detection form, analyze the composition of biotechnology through analyzing the interactions between target cells and the immune system through the introduction of nanotechnology. Additionally, due to these technological advancements, researchers are able to differentiate different forms of tumor and also apply nanotechnology and technological innovation to better target tumors and genetic mutations. However, when making these conclusions on the interventions of Artificial Intelligence and Machine Learning, it is imperative to also consider some of the ethical limitations that have been witnessed, especially in the lack of accessibility to alternative therapeutics, clinical trials and R&D in less privileged communities, especially low-income households. As continuous funds and researchers invest into these ongoing research studies, it is crucial to acknowledge that proper informed consent and appropriate disclosure must be extended to patients, to ensure that potential extraneous variables are limited, as much as possible.

References

Adir, Omer, et al. "Integrating artificial intelligence and nanotechnology for precision cancer medicine." Advanced Materials 32.13 (2020): 1901989.

Arranja, Alexandra G., et al. "Tumor-targeted nanomedicines for cancer theranostics." Pharmacological research 115 (2017): 87-95.

Conrad, Ombline, et al. "Tumor-suppressive and immunomodulating activity of miR-30a-3p and miR-30e-3p in HNSCC cells and tumoroids." International Journal of Molecular Sciences 24.13 (2023): 11178.

Hayes, Bryony, et al. "Developments in point-of-care diagnostic technology for cancer detection." Diagnostics 8.2 (2018): 39.

Liao, Jinzhuang, et al. "Artificial intelligence assists precision medicine in cancer treatment." Frontiers in oncology 12 (2023): 998222.

Moten, Asad, Daniel Schafer, and Mauro Ferrari. "Redefining global health priorities: Improving cancer care in developing settings." Journal of global health 4.1 (2014).

Nelakurthi, Vidya Maheswari, Priyanka Paul, and Amit Reche. "Bioinformatics in Early Cancer Detection." Cureus 15.10 (2023).

Soper, Steven A., et al. "Point-of-care biosensor systems for cancer diagnostics/prognostics." Biosensors and Bioelectronics 21.10 (2006): 1932-1942.

Yim, Wen-wai, et al. "Natural language processing in oncology: a review." JAMA oncology 2.6 (2016): 797-804.